FI58500C - Foerfarande foer framstaellning av ett giftfritt immunogent fragment b ur tetanustoxin - Google Patents
Foerfarande foer framstaellning av ett giftfritt immunogent fragment b ur tetanustoxin Download PDFInfo
- Publication number
- FI58500C FI58500C FI772305A FI772305A FI58500C FI 58500 C FI58500 C FI 58500C FI 772305 A FI772305 A FI 772305A FI 772305 A FI772305 A FI 772305A FI 58500 C FI58500 C FI 58500C
- Authority
- FI
- Finland
- Prior art keywords
- fragment
- tetanus toxin
- molecular weight
- tetanus
- sodium dodecyl
- Prior art date
Links
- 239000012634 fragment Substances 0.000 title claims description 47
- 108010055044 Tetanus Toxin Proteins 0.000 title claims description 36
- 229940118376 tetanus toxin Drugs 0.000 title claims description 36
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- 231100000252 nontoxic Toxicity 0.000 claims description 12
- 230000003000 nontoxic effect Effects 0.000 claims description 12
- 230000002163 immunogen Effects 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 8
- 108091005804 Peptidases Proteins 0.000 claims description 7
- 102000035195 Peptidases Human genes 0.000 claims description 7
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 7
- 238000001502 gel electrophoresis Methods 0.000 claims description 7
- 235000019833 protease Nutrition 0.000 claims description 7
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 4
- 230000008105 immune reaction Effects 0.000 claims description 4
- 238000004062 sedimentation Methods 0.000 claims description 3
- 239000007983 Tris buffer Substances 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 229960005367 tetanus antitoxin Drugs 0.000 claims description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 238000001962 electrophoresis Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000000047 product Substances 0.000 description 9
- 108090000526 Papain Proteins 0.000 description 7
- 239000004365 Protease Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 229940055729 papain Drugs 0.000 description 7
- 235000019834 papain Nutrition 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 206010043376 Tetanus Diseases 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 210000002196 fr. b Anatomy 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 231100000668 minimum lethal dose Toxicity 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 229920001425 Diethylaminoethyl cellulose Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010041415 Spastic paralysis Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- -1 diethylaminoethylcellulose ion Chemical class 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 229940124452 immunizing agent Drugs 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000010421 standard material Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2634584A DE2634584C3 (de) | 1976-07-31 | 1976-07-31 | Atoxisches, immunogenes Produkt aus Tetanus-Toxin |
| DE2634584 | 1976-07-31 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI772305A FI772305A (xx) | 1978-02-01 |
| FI58500B FI58500B (fi) | 1980-10-31 |
| FI58500C true FI58500C (fi) | 1981-02-10 |
Family
ID=5984461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI772305A FI58500C (fi) | 1976-07-31 | 1977-07-28 | Foerfarande foer framstaellning av ett giftfritt immunogent fragment b ur tetanustoxin |
Country Status (18)
| Country | Link |
|---|---|
| JP (1) | JPS5326319A (xx) |
| AT (1) | AT362498B (xx) |
| AU (1) | AU516191B2 (xx) |
| BE (1) | BE857373A (xx) |
| CA (1) | CA1099635A (xx) |
| DE (1) | DE2634584C3 (xx) |
| DK (1) | DK342577A (xx) |
| EG (1) | EG12732A (xx) |
| FI (1) | FI58500C (xx) |
| FR (1) | FR2360315A1 (xx) |
| GB (1) | GB1570958A (xx) |
| IE (1) | IE45539B1 (xx) |
| IL (1) | IL52617A (xx) |
| IT (1) | IT1085660B (xx) |
| LU (1) | LU77874A1 (xx) |
| NL (1) | NL7708279A (xx) |
| NO (1) | NO772704L (xx) |
| SE (1) | SE7708693L (xx) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8516442D0 (en) * | 1985-06-28 | 1985-07-31 | Wellcome Found | Cloned antigen |
-
1976
- 1976-07-31 DE DE2634584A patent/DE2634584C3/de not_active Expired
-
1977
- 1977-07-26 NL NL7708279A patent/NL7708279A/xx not_active Application Discontinuation
- 1977-07-27 EG EG446/77A patent/EG12732A/xx active
- 1977-07-27 AU AU27380/77A patent/AU516191B2/en not_active Expired
- 1977-07-28 FI FI772305A patent/FI58500C/fi not_active IP Right Cessation
- 1977-07-28 SE SE7708693A patent/SE7708693L/ not_active Application Discontinuation
- 1977-07-29 GB GB31968/77A patent/GB1570958A/en not_active Expired
- 1977-07-29 IE IE1590/77A patent/IE45539B1/en unknown
- 1977-07-29 DK DK342577A patent/DK342577A/da not_active Application Discontinuation
- 1977-07-29 JP JP9213677A patent/JPS5326319A/ja active Pending
- 1977-07-29 IL IL52617A patent/IL52617A/xx unknown
- 1977-07-29 NO NO772704A patent/NO772704L/no unknown
- 1977-07-29 LU LU77874A patent/LU77874A1/xx unknown
- 1977-07-29 CA CA283,802A patent/CA1099635A/en not_active Expired
- 1977-07-29 AT AT563477A patent/AT362498B/de not_active IP Right Cessation
- 1977-07-29 IT IT26354/77A patent/IT1085660B/it active
- 1977-08-01 FR FR7723600A patent/FR2360315A1/fr active Granted
- 1977-08-01 BE BE179821A patent/BE857373A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FR2360315B1 (xx) | 1980-04-11 |
| IE45539B1 (en) | 1982-09-22 |
| DE2634584B2 (de) | 1979-03-22 |
| DK342577A (da) | 1978-02-01 |
| DE2634584C3 (de) | 1979-11-08 |
| GB1570958A (en) | 1980-07-09 |
| JPS5326319A (en) | 1978-03-11 |
| AU516191B2 (en) | 1981-05-21 |
| IL52617A0 (en) | 1977-10-31 |
| EG12732A (en) | 1979-09-30 |
| IE45539L (en) | 1978-01-31 |
| NL7708279A (nl) | 1978-02-02 |
| FI772305A (xx) | 1978-02-01 |
| SE7708693L (sv) | 1978-02-01 |
| DE2634584A1 (de) | 1978-02-02 |
| BE857373A (fr) | 1978-02-01 |
| IT1085660B (it) | 1985-05-28 |
| NO772704L (no) | 1978-02-01 |
| CA1099635A (en) | 1981-04-21 |
| LU77874A1 (xx) | 1978-02-02 |
| FI58500B (fi) | 1980-10-31 |
| AU2738077A (en) | 1979-02-01 |
| IL52617A (en) | 1980-12-31 |
| ATA563477A (de) | 1980-10-15 |
| AT362498B (de) | 1981-05-25 |
| FR2360315A1 (fr) | 1978-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rush et al. | The interaction of dopamine-β-hydroxylase with concanavalin A and its use in enzyme purification | |
| Olins et al. | Reconstitution of 7S molecules from L and H polypeptide chains of antibodies and γ-globulins | |
| Willis et al. | Preparation of the periplasmic binding proteins from Salmonella typhimurium and Escherichia coli | |
| Goldberg | Immunochemical specificity of lactate dehydrogenase-X | |
| Mekalanos et al. | Purification of cholera toxin and its subunits: new methods of preparation and the use of hypertoxinogenic mutants | |
| Yan et al. | Multiple forms of pyrophosphate: D-fructose-6-phosphate 1-phosphotransferase from wheat seedlings. Regulation by fructose 2, 6-bisphosphate. | |
| Buchanan et al. | Activation of the cell wall degrading protease, lysin, during sexual signalling in Chlamydomonas: the enzyme is stored as an inactive, higher relative molecular mass precursor in the periplasm. | |
| Hoffschulte et al. | Identification of a soluble SecA/SecB complex by means of a subfractionated cell-free export system. | |
| JPH03191789A (ja) | 百日咳菌からの６９０００ダルトンの抗原性タンパク質の精製方法 | |
| Amos et al. | Synthesis of ‘bacterial’protein by cultured chick cells | |
| Heumann et al. | Purification and immunological characterization of the human hexokinase isoenzymes I and III (ATP-D-hexose 6-phosphotransferase EC 2.7. 1.1) | |
| Crofton | Site of alkaline phosphatase attachment in alkaline phosphatase-immunoglobulin G complexes | |
| Jenkins et al. | Extracellular antigens from Listeria monocytogenes I. purification and resolution of hemolytic and lipolytic antigens from culture filtrates of Listeria monocytogenes | |
| Anderson et al. | Borohydride reduction of L-glutamate decarboxylase | |
| JPH07502896A (ja) | 連鎖球菌の多官能性表面タンパク | |
| FI58500C (fi) | Foerfarande foer framstaellning av ett giftfritt immunogent fragment b ur tetanustoxin | |
| Phillips et al. | Immunological characterization of human liver α-d-mannosidase | |
| Lerman | Characterization of the insoluble protein fraction in the ocular lens | |
| EP0298991B1 (en) | Novel lectins derived from bacterial pili | |
| Suzuki et al. | Isolation and some properties of glyceraldehyde 3-phosphate dehydrogenase from vegetative cells of Bacillus cereus | |
| Robinson et al. | STUDIES WITH STAPHYLOCOCCAL TOXINS: IV. THE PURIFICATION AND METALLIC REQUIREMENTS OF SPECIFIC HEMOLYSINS | |
| JPS60146154A (ja) | オステオカルシン関連誘導体 | |
| RU2230325C2 (ru) | Способ приготовления очищенного препарата ботулинического токсина типа а | |
| Hannestad et al. | Multiple M-components in a single individual-iI studies on urinary Fab μ like fragments in macroglobulinema | |
| Miller et al. | Formation and action of a peptidase which hydrolyzes histidine peptides required in tetanus toxin synthesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed |
Owner name: BEHRINGWERKE AKTIENGESELLSCHAFT |